A team of Pillsbury lawyers represented Vincerx Pharma, Inc. in its business combination with LifeSci Acquisition Corp. and the listing of Vincerx Pharma’s common stock on the Nasdaq Capital Market. The transaction totaled $62 million at closing, with earnouts of up to an additional $60 million. Upon the closing, the market value of the combined company was $280 million.
Vincerx Pharma, Inc. is a privately held biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics.
LifeSci Acquisition Corp. is a blank check company targeting the biopharma, medical technology, digital health and healthcare services sectors.
Read more about the transaction here.
The Pillsbury team was led by Silicon Valley-based Corporate partner Tom Thomas and included partners Gabriella Lombardi and Jarrod Murphy, associates Julie Park, Lana Persaud, Andrew Clark and Jasmine Alves; Tax partner C. Brian Wainwright; and Executive Compensation & Benefits partner Cindy Schlaefer and counsel Colleen Lamarre.